Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 16;109(9):736-741.
doi: 10.1136/archdischild-2024-327153.

Effectiveness of nirsevimab immunoprophylaxis against respiratory syncytial virus-related outcomes in hospital and primary care settings: a retrospective cohort study in infants in Catalonia (Spain)

Ermengol Coma  1 , Montserrat Martinez-Marcos  2 , Eduardo Hermosilla  1   3 , Jacobo Mendioroz  4 , Anna Reñé  1 , Francesc Fina  1 , Aida Perramon-Malavez  5 , Clara Prats  5 , Gloria Cereza  6   7 , Pilar Ciruela  4   8 , Valentí Pineda  9 , Andrés Antón  10 , Gemma Ricós-Furió  11   12 , Antoni Soriano-Arandes  13 , Carmen Cabezas  4
Affiliations

Effectiveness of nirsevimab immunoprophylaxis against respiratory syncytial virus-related outcomes in hospital and primary care settings: a retrospective cohort study in infants in Catalonia (Spain)

Ermengol Coma et al. Arch Dis Child. .

Abstract

Background: In Catalonia, infants under 6 months old were eligible to receive nirsevimab, a novel monoclonal antibody against respiratory syncytial virus (RSV). We aimed to analyse nirsevimab's effectiveness across primary and hospital care outcomes.

Methods: Retrospective cohort study from 1 October 2023 to 31 January 2024, including all infants born between April and September 2023. We established two cohorts based on nirsevimab administration (immunised and non-immunised). We followed individuals until the earliest moment of an outcome-RSV infection, primary care attended bronchiolitis and pneumonia, hospital emergency visits due to bronchiolitis, hospital admission or intensive care unit (ICU) admission due to RSV bronchiolitis-death or the end of the study. We used the Kaplan-Meier estimator and fitted Cox regression models using a calendar time scale to estimate HRs and their 95% CIs.

Results: Among 26 525 infants, a dose of nirsevimab led to an adjusted HR for hospital admission due to RSV bronchiolitis of 0.124 (95% CI: 0.086 to 0.179) and an adjusted HR for ICU admission of 0.099 (95% CI: 0.041 to 0.237). Additionally, the adjusted HRs observed for emergency visits were 0.446 (95% CI: 0.385 to 0.516) and 0.393 (95% CI: 0.203 to 0.758) for viral pneumonia, 0.519 (95% CI: 0.467 to 0.576) for bronchiolitis attended in primary care and 0.311 (95% CI: 0.200 to 0.483) for RSV infection.

Conclusion: We demonstrated nirsevimab's effectiveness with reductions of 87.6% and 90.1% in hospital and ICU admissions, respectively. These findings offer crucial guidance for public health authorities in implementing RSV immunisation campaigns.

Keywords: Child Health; Immunisation; Infectious Disease Medicine; Respiratory Medicine.

PubMed Disclaimer

Conflict of interest statement

Competing interests: AS-A has received an honorarium for attending scientific meetings from Sanofi, MSD and Pfizer. VP has received an honorarium for attending scientific meetings from Sanofi and Pfizer. AA has received sponsorship from Sanofi to attend scientific meetings.

Figures

Figure 1
Figure 1
Population flow chart.
Figure 2
Figure 2
Estimated risk of hospital and intensive care unit (ICU) admissions due to bronchiolitis caused by respiratory syncytial virus according to immunisation status.
Figure 3
Figure 3
Estimated risk of RSV infections, primary care attended bronchiolitis, viral pneumonia and hospital emergency visits according to immunisation status. RSV, respiratory syncytial virus.
See this image and copyright information in PMC

References

    1. Li Y, Wang X, Blau DM, et al. . Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. The Lancet 2022;399:2047–64. 10.1016/S0140-6736(22)00478-0 - DOI - PMC - PubMed
    1. Calvo C, Pozo F, García‐García M, et al. . Detection of new respiratory viruses in hospitalized infants with bronchiolitis: a three-year prospective study. Acta Paediatrica 2010;99:883–7. 10.1111/j.1651-2227.2010.01714.x - DOI - PMC - PubMed
    1. Gimferrer L, Vila J, Piñana M, et al. . Virological surveillance of human respiratory syncytial virus A and B at a tertiary hospital in Catalonia (Spain) during five consecutive seasons (2013-2018). Future Microbiol 2019;14:373–81. 10.2217/fmb-2018-0261 - DOI - PubMed
    1. Drysdale SB, Cathie K, Flamein F, et al. . Nirsevimab for prevention of hospitalizations due to RSV in infants. N Engl J Med 2023;389:2425–35. 10.1056/NEJMoa2309189 - DOI - PubMed
    1. Simões EAF, Madhi SA, Muller WJ, et al. . Efficacy of Nirsevimab against respiratory syncytial virus lower respiratory tract infections in Preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials. Lancet Child Adolesc Health 2023;7:180–9. 10.1016/S2352-4642(22)00321-2 - DOI - PMC - PubMed

MeSH terms

Substances